2021-09-24| Asia-Pacific

Foxconn Subsidiary Invests $90.8 Million in Taiwanese CDMO, EirGenix

by Joy Lin
Share To

Foxconn Technology Group Co., a subsidiary of Hon Hai Precision (Foxconn), announced Wednesday that it acquired a private placement from EirGenix Inc., a Taiwanese contract development and manufacturing organization (CDMO).

The company purchased 27,500 EirGenix shares at NT$91.50 ($3.30) each, for a total value of NT$2.5 billion ($90.8 million). News of the investment brought EirGenix’s share price up NT$6.50 ($0.23) to close at NT$140 ($5.05) on September 22nd, a 4.87% increase.

Considering the closing price, Foxconn Technology’s private buyout enjoyed a 35% discount, which was quite the bargain. The move puts Foxconn Technology’s stake in EirGenix at 9.21%, making it the second-largest shareholder after Terry Gou.

In April, the billionaire Foxconn founder and former chairman dished out around twice the money to acquire an 18.56% stake in EirGenix through his private company, Hung Wei Technology. The cash injections from Hung Wei and Foxconn Technology will spur EirGenix’s expansion into the global CDMO industry and the development of its biosimilar pipeline.


What Does EirGenix Do?

EirGenix offers contract services ranging from the development and manufacture of cell lines to antibody-drug conjugates (ADCs). On the other hand, its products include a COVID-19 rapid testing kit and a carrier protein for vaccine delivery. In addition, the company has a product pipeline of 7 biosimilars, 4 of which target the mutated HER2 protein in breast cancer.

© All rights reserved. Collaborate with us:
Related Post
The 8 Companies Propelling Taiwan’s Biopharma Industry
How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen
Samsung Biologics Initiates Production of Moderna’s COVID-19 Vaccine
10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub
Shaping the Future of the Beauty Industry: Can Skin Microbiome Products Succeed Cosmetics?
Sanofi, Regeneron’s Dupixent Shines in Phase 3 Trial for Prurigo Nodularis
ReCode Therapeutics Raises $80 Million in Series B to Advance Gene Therapy & LNP Delivery Platform
Intellia’s CRISPR Drug Claims FDA Orphan Drug Designation to Treat ATTR Amyloidosis
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
Daiichi Sankyo to Launch mRNA Covid-19 Vaccine in 2022, Shionogi Presents Clinical Results of Covid-19 Oral Drug
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!